Chimeric Antigen Receptors Targeting CD79B and CD19 for Cancer Treatment
Summary
USPTO granted Patent US12600760B2 to The General Hospital Corporation on April 14, 2026, covering chimeric antigen receptors (CARs) targeting CD79B and CD19 for cancer treatment. The patent includes methods for producing T cells with CARs having extracellular domains that bind both CD79b and CD19. Invented by Marcela V. Maus, the patent covers upfront treatment methods where the patient has not been previously treated for the cancer.
What changed
USPTO issued Patent US12600760B2 to The General Hospital Corporation on April 14, 2026, granting exclusive rights to chimeric antigen receptor (CAR) compositions targeting both CD79B and CD19 antigens. The patent covers methods of treating cancer patients who have not received prior treatment, including administering therapeutically effective amounts of CAR-modified T cells with dual-binding extracellular domains.
Affected parties in the pharmaceutical and biotechnology sectors should monitor this patent landscape for potential licensing requirements or freedom-to-operate considerations. Healthcare providers and clinical investigators involved in CAR-T therapy development and treatment protocols may need to consider intellectual property implications when developing similar treatment regimens targeting these specific antigen combinations.
Archived snapshot
Apr 17, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Chimeric antigen receptors targeting CD79B and CD19
Grant US12600760B2 Kind: B2 Apr 14, 2026
Assignee
The General Hospital Corporation
Inventors
Marcela V. Maus
Abstract
Described herein are upfront methods for treating a patient suffering from a cancer. The method includes administering to the patient a therapeutically effective amount of an anti-cancer therapy including a chimeric antigen receptor (CAR) including an extracellular domain including a CD79b-binding domain and a CD19-binding domain, wherein the patient has not been previously treated for the cancer. The invention accordingly also relates to methods of producing and utilizing, e.g., T cells including CARs having an extracellular domain that binds CD79b and CD19.
CPC Classifications
C07K 14/7051 C07K 14/70578 A61K 40/11 A61K 40/31 A61K 40/421 A61K 40/4211 A61K 2239/28 C12N 5/0636
Filing Date
2019-12-13
Application No.
17312744
Claims
11
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.